KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Cost of Revenue: 2009-2024

Historic Cost of Revenue for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $159.4 million.

  • Halozyme Therapeutics' Cost of Revenue rose 11.77% to $55.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.1 million, marking a year-over-year increase of 13.20%. This contributed to the annual value of $159.4 million for FY2024, which is 17.13% down from last year.
  • According to the latest figures from FY2024, Halozyme Therapeutics' Cost of Revenue is $159.4 million, which was down 17.13% from $192.4 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Cost of Revenue registered a high of $192.4 million during FY2023, and its lowest value of $43.4 million during FY2020.
  • For the 3-year period, Halozyme Therapeutics' Cost of Revenue averaged around $163.7 million, with its median value being $159.4 million (2024).
  • Per our database at Business Quant, Halozyme Therapeutics' Cost of Revenue skyrocketed by 87.73% in 2021 and then dropped by 17.13% in 2024.
  • Halozyme Therapeutics' Cost of Revenue (Yearly) stood at $43.4 million in 2020, then soared by 87.73% to $81.4 million in 2021, then soared by 71.11% to $139.3 million in 2022, then skyrocketed by 38.09% to $192.4 million in 2023, then dropped by 17.13% to $159.4 million in 2024.